|Page (1) of 1 - 06/12/18||email article||print page|
(June 12, 2018)
According to a recent report published by Reports Monitor, Global Immunoassay Market is estimated to grow at a significant CAGR over the forecast period.
Immunoassay is the process of biochemical testing that is done to determine the concentration of a macromolecule in the solution using antibody or antigen. Such detectable macromolecule in the solutions is called as an analyte. Immunoassay has the provision of measuring the quantity of low concentration compounds or analytes in urine and serum. Immunoassay test is used to ensure accuracy and to analyse radioactivity procedures, the qualitative and quantitative control measures. Immunoassays are the high sensitivity test which is used for improved results and faster reactions. Immunoassay technology is specifically used for the valuable study of compounds in low volumes, which include picogram and nanogram concentrations.
According to National Aids Control Organisation, Elisa test is more effective to detect HIV than nucleic test and distributed fourth-generation Elisa testing kits to public blood banks. Moreover, Melanoma Research Alliance and American Cancer Society made a grant-making strategy partnership to minimize the side effect of immunotherapy and finding the better solutions of treatment.
Download Sample PDF Report: https://www.reportsmonitor.com/request_sample/1514
Major drivers in the market are the rising prevalence of infectious and chronic disease, rising use of immunoassay in oncology, and high adoption of immunoassay-based rapid testing that have expected to propel the growth of the market. In addition, technological advancements and stringent laws associated with drug and alcohol consumption testing are the important factors that have led the significant growth. However, low detection limit, lack of awareness about immunoassay techniques and high cost of testing are the factors that may impede the growth. On the other hand, rising importance of diagnostics associated with immunoassay market is the major factor that is providing the opportunity to propel the growth in the market.
Geographically, the market can be analysed into North America, Europe, Asia- Pacific and LAMEA. North America market is expected to be dominant in the market owing to increasing use of immunoassay technology in cancer research, high adoption of low cost and improved quality of healthcare infrastructure for clinical research. The Asia Pacific region is expected to be fastest growing market due to factors such as continuous expansion of medical treatment and solution for infectious diseases, the rising research & development for new biologics, vaccines and drugs. Moreover, the rising numbers of diagnostics laboratories, enhanced focus on attracting international and regional competitors in the market.
View Full Report Description with TOC: https://www.reportsmonitor.com/report/1514/Immunoassay-Market
Prominent players in the market are Roche Diagnostics, Siemens Healthcare, Abbott Laboratories Inc., Thermo Fisher Scientific, Becton Dickinson and Company, Meridian Life Science Inc., BioMrieux, Beckman Coulter, Danaher Corporation and Sysmex Corporation.
In 2016, the market leader of immunoassay Roche Diagnostics launched the immunochemistry equipment cobas e 801 module to meet the demand of challenging environment of the healthcare industry and to help patients for rapid diagnostics testing. The cobas e 801 module is the improved and enhanced technology of the cobas 8000 modular analyzer series. It provides efficient testing capacity which is twice the capacity of the presently available equipment on the same footprint. It delivers reliable and fast results with high accuracy and consistency.
Moreover, Meridian Life Sciences, Inc. launched the most powerful immunoassay interference blocker TRU Block ULTRA in 2017. It provides numerous benefits including active blocking technology, interference blocking against rheumatoid factor (RH), human anti-mouse antibodies (HAMA) and heterophilic antibodies.
In September 2017, ArcticZymes a subsidiary of Biotec Pharmacon has launched new immunoassay product “SAN HQ ELISA”, which provides complete solutions associated with critical elimination of DNA contamination.
Get Discount on this Report: https://www.reportsmonitor.com/check_discount/1514
By Product & Service
• Reagents & Kits
• Software Services
• Infectious Disease
• Rapid Test
• Western Blot
By End User
• Clinical Laboratories
• Blood Banks
• Pharmaceutical & Biotechnology Companies
• North America (U.S and Canada)
• Europe (Germany, France, Italy and Rest of Europe)
• Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
• LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)
View More Reports of Pharmaceuticals and Healthcare Industry
Company Name: Reports Monitor
Contact Person: Jay Matthews
Email: [email protected]
Phone: +1 513 549-5911
Related Keywords:Fitness,Health & Medicine,Pharmaceuticals & Biotech,Science,Technology,
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter